Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of active fragment of platelet reactive protein 1 in medicine for treating ocular neovascularization diseases

A technology of reactive protein and active fragments, which is applied in cardiovascular system diseases, sensory diseases, drug combinations, etc., can solve the problems of less research and application of active fragments of thrombospondin 1, and achieve favorable treatment, simple manufacturing process, and production process steps little effect

Pending Publication Date: 2020-08-04
田润
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In view of the deficiencies in the prior art, the present invention provides an application of the active fragment of thrombospondin 1 in the treatment of ocular neovascular diseases, which solves the problem of less research and application of the active fragment of thrombospondin 1 VR-10

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of active fragment of platelet reactive protein 1 in medicine for treating ocular neovascularization diseases
  • Application of active fragment of platelet reactive protein 1 in medicine for treating ocular neovascularization diseases
  • Application of active fragment of platelet reactive protein 1 in medicine for treating ocular neovascularization diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] An embodiment of the present invention provides a drug for treating ocular neovascular diseases with the active fragment of thrombospondin 1, and the components of the drug include VR-10, the active fragment of thrombospondin 1.

[0022] The production process of the drug for the treatment of ocular neovascular diseases by the active fragment of thrombospondin 1 includes the following contents: VR-10 is synthesized by chemical synthesis with a purity of 99%.

[0023] The peptide chain sequence of thrombospondin 1 active fragment VR-10 is valine-threonine-cysteine-glycine-valine-isoleucine-threonine-arginine-isoleucine -Arginine, the active fragment of thrombospondin 1, VR-10, inhibits neovascularization by reducing VEGF and inflammation-related factors.

Embodiment 2

[0025] experiment one:

[0026] 1 operation

[0027] Using minimum essential medium (MEM) containing 10% bovine serum albumin (BSA), the rhesus monkey chorioretinal endothelial cell line (RF / 6A) was placed in 5% CO 2 , 95% air, 90% humidity, and cultured in a 37°C cell incubator, and the culture medium was replaced the next day.

[0028] The experiment was divided into control group and intervention group. The intervention groups included 0.1, 1.0, 10.0 μg / ml thrombospondin 1 active fragment (VR-10) group and 1.0 μg / ml thrombospondin 1 (TSP-1) whole peptide group. Cells in each group were cultured in complete medium containing 10% fetal bovine serum (FBS), and the intervention group intervened cells with corresponding concentrations and drugs on this basis.

[0029] The thiazolium blue (MTT) method was used to detect the survival rate of RF / 6A cells in intervention maggots. Seed cells at 100 μl / well at a density of about 1×10 4 cells / ml, in 5% CO 2 Incubate for 6, 12, 24...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of an active fragment of platelet reactive protein 1 in treating ocular neovascularization diseases, and relates to the field of pharmacy. The platelet reactive protein 1 active fragment is a medicine for treating ocular neovascularization diseases, and the medicine production component is VR-10. The platelet reactive protein 1 active fragment VR-10 can be applied to treatment of ocular neovascularization diseases.

Description

technical field [0001] The invention relates to the technical field of pharmaceuticals, in particular to the application of active fragments of thrombospondin 1 in the medicine for treating ocular neovascular diseases. Background technique [0002] Previous studies have found that the expression of thrombospondin-1 (TSP-1) in human retinal pigment epithelial cells decreases with time under hypoxic conditions, and it may participate in the occurrence and development of angiogenesis diseases as a negative factor of angiogenesis . In recent years, there have been more and more studies on the role of TSP-1 in the eye, but the specific role of TSP-1 in ocular neovascularization is still unclear. Studies have shown that TSP-I is a macromolecular glycoprotein with a complex structure, and type I repeat sequences (TSRs) are considered to be the structural basis for inhibiting endothelial cell proliferation, inducing endothelial cell apoptosis, and inhibiting angiogenesis. Endothel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/08A61P27/02A61P9/10
CPCA61K38/08A61P27/02A61P9/10
Inventor 田润庞晓丛张智崔一民
Owner 田润
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com